Amy Goodman
@DemocracyNow·3.2M subscribers·19.4K videos
Why Are We Paying $300 for an EpiPen That Holds Only $1 Worth of Medicine?
Posted
August 30, 2016
Views
8,944
Likes
229
Comments
99
Engagement
3.67%
August 30, 2016
8,944
229
99
3.67%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
6:59Now PlayingIn 2007, the wholesale price of the EpiPen in the U.S. was $57. Less than a decade later, the lifesaving drug now costs over $300. Each EpiPen reportedly contains only $1 worth of medicine. Mylan has a near monopoly in the U.S., and the company has seen its profits from the EpiPen alone skyrocket to $1 billion a year. Meanwhile, Mylan CEO Heather Bresch’s total compensation has spiked from around $2.5 million in 2007 to almost $19 million today. In response to the price hikes, the consumer advocacy group Public Citizen and its allies will deliver a petition signed by approximately 600,000 people to Mylan’s headquarters in Canonsburg, Pennsylvania, today demanding further price cuts. For more, we speak with Peter Maybarduk, director of Public Citizen’s Global Access to Medicines Program. And we speak with Ashley Alteman, who runs a website called SmashleyAshley.com, where she has just posted an open letter to Mylan CEO Heather Bresch.
Democracy Now! is an independent global news hour that airs weekdays on nearly 1,400 TV and radio stations Monday through Friday. Watch our livestream 89AM ET
Please consider supporting independent media by making a donation to Democracy Now! today
FOLLOW DEMOCRACY NOW! ONLINE:
Daily Email
Stitcher Radio
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
